Susan Altschuller | VP, IR |
Ludwig Hantson | CEO & Director |
Paul Clancy | EVP & CFO |
John Orloff | EVP and Head, Research & Development |
Brian Goff | EVP & Chief Commercial Officer |
Geoff Meacham | Barclays |
Kennen MacKay | RBC Capital Markets |
Geoffrey Porges | SVB Leerink |
Paul Matteis | Stifel |
Chris Raymond | Piper Jaffray |
Phil Nadeau | Cowen and Company |
Josh Schimmer | Evercore ISI |
Matthew Harrison | Morgan Stanley |
Robyn Karnauskas | Citi |
Steven Seedhouse | Raymond James |
Ying Huang | Bank of America Merrill Lynch |
Good morning. And welcome to the Alexion Pharmaceuticals Incorporated Conference Call to discuss First Quarter 2019 Financial Results. Today's call is being recorded.
For opening remarks and introductions, I would now like to turn the call over to Susan Altschuller, Vice President Investor Relations. Please go ahead, ma'am.